Camp4 Therapeutics highlighted its SYNGAP1 research as part of a broader push into developmental and epileptic encephalopathies. At the ILAE and epiCare confere

Camp4 Therapeutics highlighted its SYNGAP1 research as part of a broader push into developmental and epileptic encephalopathies. At the ILAE and epiCare conference, it outlined a regRNA-targeting approach designed to upregulate gene expression.